1,069 results match your criteria Future Cardiology[Journal]


Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance.

Authors:
Yidong Wei Wen Xu

Future Cardiol 2019 Feb 22. Epub 2019 Feb 22.

Department of Endocrinology & Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.

Many studies indicated postprandial hyperglycemia was closely related to the development of diabetes and the risk of cardiovascular disease. Acarbose was shown to delay the onset of diabetes in people with impaired glucose tolerance that was at low cardiovascular risk. The Acarbose Cardiovascular Evaluation (ACE) trial formally evaluated whether acarbose could reduce the frequency of cardiovascular events in patients with established coronary heart disease and impaired glucose tolerance, and whether the incidence of Type 2 diabetes could be reduced. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0062DOI Listing
February 2019

Rivaroxaban for prevention and treatment of venous thromboembolism.

Future Cardiol 2019 Feb 19. Epub 2019 Feb 19.

Thrombosis & Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada.

Until recently, heparins and vitamin K antagonists (VKAs) were the cornerstones for prevention and treatment of venous thromboembolism (VTE). This situation changed with the introduction of the direct oral anticoagulants, which are now replacing low-molecular-weight heparin for thromboprophylaxis after elective hip or knee arthroplasty and VKAs for VTE treatment. Rivaroxaban, an oral factor Xa inhibitor, was the first direct oral anticoagulant licensed for VTE prevention and treatment. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fca-2018-0076
Publisher Site
http://dx.doi.org/10.2217/fca-2018-0076DOI Listing
February 2019
1 Read

Tafamidis for the treatment of transthyretin amyloidosis.

Future Cardiol 2019 Feb 15. Epub 2019 Feb 15.

University College London Institute for Cardiovascular Science & Barts Heart Centre, St Bartholomew's Hospital, London, UK.

Transthyretin (TTR) related cardiomyopathy is an underdiagnosed cause of heart failure but is increasingly recognized in various settings - from patients admitted with heart failure to symptomatic aortic stenosis - and is rapidly becoming the most frequent form of systemic amyloidosis. Following the recent publication of the landmark ATTR-ACT trial that showed tafamidis to be the first treatment to improve survival in patients with TTR-related cardiac amyloidosis and heart failure, we reviewed the drug's rationale, characteristics and evidence supporting its use in TTR amyloidosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0078DOI Listing
February 2019
1 Read

Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study.

Future Cardiol 2019 01 21. Epub 2019 Jan 21.

Dipartimento Medico Azienda USL di Bologna. Unità Operativa di Cardiologia Ospedale Maggiore, Bologna, Italy.

Aim: To evaluate antithrombotic treatment patterns in patients in Italy with nonvalvular atrial fibrillation (NVAF) before and after direct oral anticoagulants (DOACs) were approved.

Methods: This analysis included patients with a discharge diagnosis of NVAF in 2010 and 2014, which constituted the pre- and post-DOACs populations, respectively.

Results: Approximately 90% of patients were eligible for oral anticoagulant (OAC) therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0009DOI Listing
January 2019
2 Reads

Treatment strategies for coronary bifurcation lesions made easy in the current era by introduction of the BIFURCAID app.

Future Cardiol 2019 01 15;15(1):39-52. Epub 2019 Jan 15.

Division of Cardiology, Mount Sinai Hospital & Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Coronary bifurcation lesions account for 15-20% of all percutaneous coronary interventions. Percutaneous revascularization of these lesions is technically challenging and results in lower success rates than nonbifurcation lesions. There are unique procedural considerations and techniques that are employed in the percutaneous revascularization of these lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0068DOI Listing
January 2019
1 Read

Self-expanding CENTERA valve for the treatment of severe, symptomatic aortic stenosis.

Future Cardiol 2019 Jan 9. Epub 2019 Jan 9.

Department of Cardiology, Royal Victoria Hospital, Belfast Health & Social Care Trust, Belfast, Country Antrim, Northern Ireland, BT12 6BA.

Transcatheter aortic valve implantation (TAVI) is now an established treatment option for both high and intermediate operative risk patients with severe symptomatic aortic stenosis. The number of patients undergoing TAVI has increased over the last decade warranting continued technological improvements in transcatheter heart valve (THV) systems. The novel CENTERA self-expanding THV (Edwards Lifesciences, CA, USA) received CE approval this year. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fca-2018-0074
Publisher Site
http://dx.doi.org/10.2217/fca-2018-0074DOI Listing
January 2019
3 Reads

Maturation from CoreValve to Evolut Pro: a clinical overview.

Future Cardiol 2019 01 19;15(1):1-8. Epub 2018 Dec 19.

Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.

The only curative treatment of aortic stenosis is through surgical or transcatheter aortic valve replacement. Transcatheter aortic valve implantation has evolved from its first in human experience in 2002 and matured to the treatment of first choice of symptomatic severe aortic stenosis in elderly patients with an elevated operative risk. The self-expanding CoreValve bioprosthesis has been on the forefront of this growing transcatheter aortic valve implantation experience. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0064DOI Listing
January 2019
1 Read

Design and evaluation of the Micra Transcatheter Pacing System for bradyarrhythmia management.

Future Cardiol 2019 01 5;15(1):9-15. Epub 2018 Dec 5.

Cardiac Rhythm Management Research Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Permanent cardiac pacemakers have traditionally comprised a surgically implanted subcutaneous pulse generator affixed to at least one transvenous pacing lead. Despite technological advances, implant-related complications and transvenous-lead failure rates have remained high. The Micra Transcatheter Pacing System is a miniaturized single chamber pacemaker that is implanted directly into the right ventricle, eliminating the subcutaneous pocket and creating a leadless pacemaker system. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fca-2018-0077
Publisher Site
http://dx.doi.org/10.2217/fca-2018-0077DOI Listing
January 2019
11 Reads

Transcatheter pulmonary valve replacement: evolving indications and application.

Future Cardiol 2018 Nov 30. Epub 2018 Nov 30.

Departments of Pediatrics & Cardiothoracic Surgery, Lucile Packard Children's Hospital Heart Center, Stanford University School of Medicine, Palo Alto, Stanford-94304-5731, CA, USA.

The introduction of transcatheter therapy for valvular heart disease has changed the spectrum of care of patients with a variety of cardiovascular conditions. Transcatheter valve placement has become established as a method of treating pathologic regurgitation or stenosis of the pulmonary valve, right ventricular outflow tract or a right ventricle to pulmonary artery conduit. In this review, we examine the pathophysiology of and indications for transcatheter pulmonary valve replacement along with procedural complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0065DOI Listing
November 2018
3 Reads

Alirocumab for low-density lipoprotein cholesterol lowering.

Authors:
Eli M Roth

Future Cardiol 2019 01 30;15(1):17-29. Epub 2018 Nov 30.

President, Sterling Research Group & Clinical Professor, Division of Cardiovascular Health & Disease, University of Cincinnati, Cincinnati, OH 45219-513, USA.

Ischemic heart disease and stroke are the leading causes of death in the world currently. Both of these conditions are primarily caused by atherosclerosis, the underlying pathophysiology of which is the deposition of lipid, specifically low-density lipoprotein cholesterol (LDL-C) within the arterial bed. PCSK9, is a proteolytic enzyme, which indirectly increases LDL-C levels by causing the destruction of LDL receptors, the main way that humans regulate their serum LDL-C levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0072DOI Listing
January 2019
9 Reads

Letter in reply to 'How to manage a spontaneous coronary artery dissection: reconsidering diagnosis and therapy'.

Future Cardiol 2018 Nov 28. Epub 2018 Nov 28.

University Hospital Limerick, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0084DOI Listing
November 2018
1 Read

The dual-therapy COMBO stent: a rationale for a light dual antiplatelet therapy treatment.

Future Cardiol 2018 Nov 27. Epub 2018 Nov 27.

Interventional Cardiology Unit, GVM Care & Research Maria Cecilia Hospital, Cotignola, 48033, Italy.

The COMBO stent is a new, sirolimus-eluting bioresorbable polymer, bioengineered stent. This technology combines the advantages of second-generation drug-eluting stents with the endothelial progenitor cell capture technology mediated by the anti-CD34 antibody coating on the COMBO luminal surface. This dual technology should improve vessel endothelium regeneration and may lay the biological basis for a short dual antiplatelet therapy course. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fca-2018-0051
Publisher Site
http://dx.doi.org/10.2217/fca-2018-0051DOI Listing
November 2018
8 Reads

The Portico transcatheter aortic valve for the treatment of severe aortic stenosis.

Future Cardiol 2019 01 27;15(1):31-37. Epub 2018 Nov 27.

Cardiovascular Surgical Department, Heart Valve Clinic, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

The Portico TAVI system (Abbott Vascular, Santa Clara, CA, USA) has been specifically designed to mitigate some of the complications associated with first-generation valves. Most of the data generated from randomized studies comparing transcatheter aortic valve implantation with surgery stem from reported experiences with first generation transcatheter heart valve devices. The aim of this review is to describe the repositionable and retrievable Portico system and its implantation technique, coupled with our single-center experience and to provide a review of the clinical results reported so far in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0070DOI Listing
January 2019
1 Read

How to manage a spontaneous coronary artery dissection: reconsidering diagnosis and therapy.

Authors:
Dario Buccheri

Future Cardiol 2018 11 22;14(6):427-429. Epub 2018 Nov 22.

Interventional cardiology unit, S. Antonio Abate Hospital, Trapani, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0006DOI Listing
November 2018
9 Reads

Mahaim fibers coexisting with coarctation of aorta and bicuspid aortic valve.

Future Cardiol 2018 Nov 13. Epub 2018 Nov 13.

Department of Medicine, University of Arizona, School of Medicine, Tucson, Arizona, USA.

We found a coexistence of Mahaim fibers, coarctation of aorta and bicuspid valve in a young patient presenting with palpitations and subraventricular tachycardia. This rare combination of these three congenital cardiac abnormalities occurring in the same patient has not been reported previously. Detailed cardiac studies unmasked the patient's cardiac abnormalities. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fca-2017-0093
Publisher Site
http://dx.doi.org/10.2217/fca-2017-0093DOI Listing
November 2018
16 Reads

Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.

Future Cardiol 2018 11 12;14(6):443-453. Epub 2018 Nov 12.

Department of Medicine, McMaster University, Hamilton, ON, L8S 4K1, Canada.

The cardiovascular outcomes for people using anticoagulation strategies (NCT01776424) trial randomized 27,395 patients with stable coronary artery disease or peripheral artery disease (PAD) to receive rivaroxaban 5 mg twice-daily alone, the combination of rivaroxaban 2.5 mg twice-daily and aspirin 100 mg daily, or aspirin 100 mg daily alone. The combination arm resulted in a 24% reduction in the primary end point of cardiovascular death, stroke or myocardial infarction, and an 18% reduction in mortality. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fca-2018-0059
Publisher Site
http://dx.doi.org/10.2217/fca-2018-0059DOI Listing
November 2018
4 Reads

Type-2 diabetes mellitus and cardiovascular disease.

Authors:
Robert J Henning

Future Cardiol 2018 Nov 9. Epub 2018 Nov 9.

University of South Florida, Tampa, FL 33612-3805, USA.

The global prevalence of diabetes has risen in adults from 4.7% in 1980 to 8.5% in 2014. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fca-2018-0045
Publisher Site
http://dx.doi.org/10.2217/fca-2018-0045DOI Listing
November 2018
10 Reads

Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program.

Future Cardiol 2018 Oct 30. Epub 2018 Oct 30.

Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Inclisiran is a novel drug that inhibits PCSK9 synthesis specifically in the liver, harnessing the natural mechanism of RNAi. Phase I and II data show that inclisiran lowers low-density lipoprotein cholesterol levels on average by >50% with a duration of effect that enables twice-yearly dosing. Phases I, II and emerging Phase III data support inclisiran's safety, tolerability and risk-benefit profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0067DOI Listing
October 2018
4 Reads

Betrixaban in the prevention of venous thromboembolism in medically ill patients.

Future Cardiol 2018 Oct 24. Epub 2018 Oct 24.

Department of Hematology, Brigham & Women's Hospital, Boston, MA, 02115, USA.

Despite significant advances in strategies and compliance with venous thromboembolism (VTE) prophylaxis, hospital-acquired VTE remains a leading cause of preventable deaths in acute medically ill patients. A majority of venous thromboembolic events occur post-hospital discharge when risk factors persist and pharmacoprophylactic regimens have been completed. Until recently, there has been an unmet need for safe and effective extended-duration VTE prevention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0052DOI Listing
October 2018
1 Read

Initial experience with a leadless pacemaker (Micra™) implantation in a low volume center in South East Asia.

Future Cardiol 2018 Sep 25. Epub 2018 Sep 25.

Consultant Cardiologist, Cardiac Centre RIPAS Hospital, Bander Seri Begawan BA1710, Brunei Darussalam.

Aim: The Micra™ Transcatheter Pacing System is a leadless pacemaker that has been introduced recently. We share our experience in a low volume center and the use of right ventricular angiography (RVA) during implantation.

Materials & Methods: Patients underwent Micra implantation and RVA was performed to predetermine the implant site. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2017-0106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190239PMC
September 2018
2 Reads

Mobile health apps preferences and practice among ambulatory cardiovascular patients.

Future Cardiol 2018 09 20;14(5):381-388. Epub 2018 Sep 20.

Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

Aim: To determine if patients in cardiology practices would be interested in or willing to use mobile health technologies.

Methods: Patients seen at an ambulatory cardiology clinic for any indication were included. A paper survey was administered during pre-intake that assessed frequency of use, familiarity with and interest in mobile health applications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0005DOI Listing
September 2018
2 Reads

The cessation of oral anticoagulation following left atrial appendage surgery.

Future Cardiol 2018 09 20;14(5):407-415. Epub 2018 Sep 20.

NHLI Cardiothoracic Surgery, B Block BN2/15, Hammersmith Hospital Campus, Imperial College Healthcare NHS Trust, Du Cane Road, London W12 0NN, England.

Atrial fibrillation is associated with a significantly increased risk of stroke, and oral anticoagulation is the mainstay of preventative treatment. Scenarios arise where the risks of treatment with oral anticoagulation may outweigh the benefits, most commonly when there is an elevated risk of bleeding. Studies of percutaneous closure of the left atrial appendage have strongly implicated this structure in the etiology of stroke in atrial fibrillation, and provide some rationale for the discontinuation of oral anticoagulation following percutaneous closure device implantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0010DOI Listing
September 2018
5 Reads

A patient with multiple Swiss cheese aspect coronary lesions: optical coherence tomography to guide coronary angioplasty.

Future Cardiol 2018 09 20;14(5):375-380. Epub 2018 Sep 20.

Cardiology Department, Mazzoni Hospital, Ascoli Piceno, Italy.

Although spontaneous recanalization of coronary thrombi has been reported pathologically, it is rarely recognized in clinical practice. We presented a rare case of recanalized thrombi of the right coronary artery and distal left anterior descending artery in a patient with an anterior ST segment elevation myocardial infarction treated with primary percutaneous intervention of the proximal left anterior descending artery. Optical coherence tomography aspect of right coronary artery was consistent with a 'Swiss cheese' appearance that represented recanalization of organized thrombi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0035DOI Listing
September 2018
2 Reads

Clinical characteristics and survival in cardiogenic shock admissions to a UK heart transplant unit.

Future Cardiol 2018 09 20;14(5):397-406. Epub 2018 Sep 20.

The Transplant Unit, University Hospital of South Manchester, Southmoor Road, Manchester M23 9LT, UK.

Aim: We describe the characteristics and outcomes of cardiogenic shock (CS) admissions to a UK transplant unit, which is previously unreported.

Patients & Methods: Fifty-nine unselected, consecutive patients over a 38-month period in CS (INTERMACS ≤2) and potentially eligible for transplant were retrospectively reviewed.

Results: Patients were predominantly male (76. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2017-0094DOI Listing
September 2018
10 Reads

Predictive value of C-reactive protein after drug-eluting stent implantation: an update view.

Future Cardiol 2018 09 20;14(5):355-358. Epub 2018 Sep 20.

Department of Cardiovascular & Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0038DOI Listing
September 2018
2 Reads

Transcatheter aortic valve replacement with the Lotus valve system.

Future Cardiol 2018 09 24;14(5):367-373. Epub 2018 Aug 24.

Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX 77030, USA.

Transcatheter aortic valve replacement has become an acceptable alternative to surgical aortic valve replacement in patients who are intermediate to high risk for surgery. The Lotus valve system (Boston Scientific, MA, USA) is an unique, mechanically expanded device. The system includes a braided nitinol frame and an adaptive seal to minimize paravalvular regurgitation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0044DOI Listing
September 2018
2 Reads

Advances in cardiac implantable electronic device infection prevention: should we push the envelope?

Future Cardiol 2018 09 31;14(5):359-366. Epub 2018 Jul 31.

Section of Cardiac Pacing & Electrophysiology, Robert & Suzanne Tomsich Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue/J2-2, Cleveland, OH 44195, USA.

Cardiac implantable electronic devices (CIEDs) including pacemakers, implantable cardioverter defibrillators and loop recorders have become widespread adjuncts in the care of patients with cardiovascular disease. CIEDs provide increased diagnostic yield, better quality of life and improved longevity. While there are obvious benefits with these devices, the mere fact that these therapies involve implantation of a foreign device within the body leads to certain risks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0039DOI Listing
September 2018
1 Read

Intra-aortic balloon pump: current evidence & future perspectives.

Future Cardiol 2018 07 28;14(4):319-328. Epub 2018 Jun 28.

Division of Cardiac Surgery & Surgical Research, Department of Surgery, McGill University, Montreal Quebec, Canada.

The intra-aortic balloon pump (IABP) is frequently used to support severely compromised ventricles in critically ill patients. Its relatively affordability and ease of insertion has cemented its position as the first line of treatment for hemodynamic support in cardiogenic shock. Accordingly, the current ACC/AHA recommendations maintain a Class 2A for the use of IABP in shock. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2017-0070DOI Listing
July 2018
2 Reads

Mitochondrial disease: learning from Charlie's lesson, trying to cure, trying much more to care.

Future Cardiol 2018 07 27;14(4):273-276. Epub 2018 Jun 27.

Cochin Hospital, Cardiology Department, Paris-Descartes, Sorbonne Paris Cité University, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0001DOI Listing
July 2018
2 Reads

New therapies for acute myocardial infarction: current state of research and future promise.

Future Cardiol 2018 07 27;14(4):329-342. Epub 2018 Jun 27.

Department of Cardiology A, Institute CARDIOMET, Clinical Center of Investigation for Biotherapies, CIC-BT 0511, INSERM 1048, University Hospital of Toulouse, Toulouse, France.

Progress has been made into research on new therapies, mechanical and pharmacological approaches and repair/regenerative cellular therapy to treat irreversible cardiovascular pathologies, such as acute myocardial infarction. Research into cellular therapies is exploring the use of new cellular types. Although the therapeutic effects of cell therapy remain modest, results from clinical trials are encouraging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2017-0047DOI Listing
July 2018
2 Reads

Prescribing patterns of oral antiplatelets in Wales: evolving trends from 2005 to 2016.

Future Cardiol 2018 07 25;14(4):277-282. Epub 2018 Jun 25.

Welsh Medicines Resource Centre, University Hospital Llandough, Cardiff, Wales, UK.

Aim: Antiplatelets have been used for decades to prevent atherothrombotic disease, but there is limited 'real-life' prescribing data. We hereby report the prescribing patterns for oral antiplatelets in Wales, UK.

Methods/results: Retrospective analysis of anonymized data in Wales from 2005 to 2016 revealed differences in prescribing patterns of oral antiplatelets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0003DOI Listing
July 2018
4 Reads

Advances in the management of cardiovascular disease during pregnancy.

Future Cardiol 2018 07 22;14(4):269-272. Epub 2018 Jun 22.

Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0033DOI Listing
July 2018
1 Read

The role of air pollution on ST-elevation myocardial infarction: a narrative mini review.

Future Cardiol 2018 07 22;14(4):301-306. Epub 2018 Jun 22.

Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran.

ST-elevation myocardial infarction (STEMI) is one of the potential causes of death worldwide. In spite of substantial advances in its diagnosis and treatment, STEMI is still considered as a major public health dilemma in developed and particularly developing countries. One of the triggering factors of STEMI is supposed to be air pollutants like gaseous pollutants including, sulfur dioxide, nitric dioxide, carbon monoxide, ozone and particulate matters (PM) including, PM under 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2017-0078DOI Listing
July 2018
2 Reads

Circulating miR-192 is a prognostic marker in patients with ischemic cardiomyopathy.

Future Cardiol 2018 07 21;14(4):283-289. Epub 2018 Jun 21.

Klinik für Anästhesiologie & Intensivmedizin, Universität Duisburg-Essen & Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany.

Ischemic cardiomyopathy (ICM) is characterized by accumulation of p53 causing apoptosis of cardiomyocytes and resulting in upregulation of miRNA (miR)-192, which plays an important role in the development of heart failure after acute myocardial infarction. However, for other cardiomyopathies, miR-192 seems to have minor relevance. We tested in a prospective, observational study comprising 91 patients with diagnosed heart failure (59. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2017-0108DOI Listing
July 2018
5 Reads

Anchor-balloon technique to facilitate stent delivery via the GuideLiner catheter in percutaneous coronary intervention.

Future Cardiol 2018 07 21;14(4):291-299. Epub 2018 Jun 21.

Cardiology Department, University Hospital Limerick, Limerick, Ireland.

Aim: The GuideLiner (GL) is a widely used catheter primarily in complex percutaneous coronary intervention (PCI). Deep seating of the GL and distal stent placement may be facilitated by the anchor-balloon technique (ABT).

Methods: We aimed to prospectively analyze procedural details, technical success, complications and in-hospital outcome in patients who underwent PCI using the GL catheter and the ABT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2017-0092DOI Listing
July 2018
2 Reads

Evolution of the SYNERGY bioresorbable polymer metallic coronary stent.

Future Cardiol 2018 07 21;14(4):307-317. Epub 2018 Jun 21.

The Christ Hospital Heart & Vascular Center/The Carl & Edyth Lindner Center for Research & Education at The Christ Hospital, 2123 Auburn Avenue, Suite 424, Cincinnati 45219, OH, USA.

The SYNERGY stent is composed of thin, platinum-chromium metal alloy struts and an ultrathin, bioabsorbable poly-DL-lactide-co-glycolide polymer limited to the abluminal strut surface which elutes everolimus prior to complete resorption within 3-4 months. SYNERGY was designed to reduce inflammation and facilitate stent healing compared with permanent polymer drug eluting stents. This review summarizes the preclinical and clinical development of SYNERGY, its integration into clinical practice and future directions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0040DOI Listing
July 2018
1 Read

Respiratory virus prophylaxis in congenital heart disease.

Future Cardiol 2018 09 7;14(5):417-425. Epub 2018 Jun 7.

Department of Congenital Heart Disease, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol BS2 8BJ, UK.

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections and causes up to 200,000 infant deaths a year worldwide. The average rate of hospitalization for severe RSV infection is 5 per 1000 children, and the rate is three-times higher in those with congenital heart disease (CHD). Palivizumab, a monoclonal antibody, reduces hospitalization rates and intensive care admissions. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fca-2017-0096
Publisher Site
http://dx.doi.org/10.2217/fca-2017-0096DOI Listing
September 2018
10 Reads

Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain.

Future Cardiol 2018 05;14(3s):3-8

Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario, Valencia, Spain.

Aim: To analyze the clinical profile and rates of stroke, major bleeding and intracranial hemorrhage of patients with atrial fibrillation (AF) treated with rivaroxaban in clinical practice.

Methods: Retrospective study of AF patients anticoagulated with rivaroxaban in a Healthcare Area of Valencia, Spain. Patients started treatment with rivaroxaban from July 2012 to December 2015. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fca-2018-0020
Publisher Site
http://dx.doi.org/10.2217/fca-2018-0020DOI Listing
May 2018
14 Reads

Drug persistence and outcomes in a cohort of patients with nonvalvular atrial fibrillation treated with rivaroxaban after 2 years of follow-up in clinical practice.

Future Cardiol 2018 05;14(3s):9-16

Department of Cardiology, Hospital Costa del Sol, Marbella, Spain.

Aim: To evaluate medication persistence and outcomes in patients with atrial fibrillation after 2 years of treatment with rivaroxaban in routine practice.

Methods: Retrospective study of atrial fibrillation patients in whom rivaroxaban was prescribed during the first quarter of 2014 in the healthcare area of Costa del Sol (Málaga).

Results: A total of 111 patients (mean age 74. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0021DOI Listing
May 2018
3 Reads

Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain.

Future Cardiol 2018 05;14(3s):17-24

Servicio Hematología y Hemoterapia, Hospital Universitario San Agustín, Avilés, Spain.

Aim: To analyze the clinical profile and outcomes of patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital.

Methods: Retrospective study of patients with nonvalvular atrial fibrillation that started treatment with rivaroxaban between July 2013 and May 2017 in a regional hospital.

Results: 189 patients (age 76. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0022DOI Listing
May 2018
2 Reads

Anticoagulation with rivaroxaban in a hematology unit: clinical profile, events and discontinuation rates in real-life patients with nonvalvular atrial fibrillation.

Future Cardiol 2018 05;14(3s):25-30

Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

Aim: To assess the clinical profile and thromboembolic and bleeding events in patients with nonvalvular atrial fibrillation (AF) who were attended in a hematology unit.

Methods: Retrospective study of AF patients that started treatment with rivaroxaban between February 2012 and June 2016 in a hematology unit from a tertiary hospital in Spain.

Results: Overall, 243 patients (mean age 78. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0023DOI Listing
May 2018
1 Read

Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke.

Future Cardiol 2018 05;14(3s):31-37

Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Aim: To evaluate the clinical profile and effectiveness/safety of patients taking rivaroxaban in clinical practice.

Methods: Retrospective study that included patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke between January 2012 and December 2016 in a tertiary hospital in Spain.

Results: A total of 142 patients (median age 78 years, 40. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0024DOI Listing
May 2018
3 Reads

Clinical profile, management and outcomes in a cohort of elderly and highly comorbid patients with nonvalvular atrial fibrillation treated with rivaroxaban in routine practice.

Future Cardiol 2018 05;14(3s):39-45

Servicio de Cardiología, Hospital General San Jorge, Huesca, Spain.

Aim: To analyze clinical profile and management of patients with nonvalvular atrial fibrillation treated with rivaroxaban in clinical practice according to age and to ascertain rates of thromboembolic and bleeding events during rivaroxaban therapy.

Methods: Retrospective study of nonvalvular atrial fibrillation patients that started rivaroxaban therapy between May 2013 and February 2017 in the cardiology department of two hospitals from Huesca, Spain.

Results: A total of 137 patients (mean age 78. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0025DOI Listing
May 2018
1 Read

Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use?

Future Cardiol 2018 05;14(3s):47-53

Unidad de Gestión Clínica de Medicina Interna, Hospital San Juan de la Cruz, Úbeda (Jaén), Spain.

Aim: To analyze the evolution of clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban.

Methods: Retrospective study in which patients treated with rivaroxaban were divided into two groups according to the data in which the initial prescription was performed (November 2012-December 2013 and January 2014-January 2017).

Results: 211 patients (mean age 76. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0026DOI Listing
May 2018
3 Reads

Rivaroxaban: from ROCKET-AF trial to routine practice in Spain.

Future Cardiol 2018 05;14(3s):1-2

Cardiology Service, Hospital Universitario La Paz, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0019DOI Listing
May 2018
1 Read

Pulmonary hypertension in congenital heart disease.

Future Cardiol 2018 07 24;14(4):343-353. Epub 2018 May 24.

Department of Congenital Heart Disease, Bristol Heart Institute, Upper Maudlin Street, Bristol, BS2 8BJ, UK.

Pulmonary hypertension is defined as a mean pulmonary arterial pressure ≥25 mmHg. We focus on its relevance in congenital heart disease, reviewing pathophysiology, diagnosis and management. Pulmonary hypertension is a relatively common complication of congenital heart disease, with adult prevalence between 5 and 10%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2017-0065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136120PMC
July 2018
6 Reads

Prehospital fibrinolysis followed by urgent percutaneous coronary intervention after ST-elevation myocardial infarction.

Future Cardiol 2018 05 16;14(3):193-195. Epub 2018 May 16.

Baylor College of Medicine, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fca-2018-0034
Publisher Site
http://dx.doi.org/10.2217/fca-2018-0034DOI Listing
May 2018
4 Reads

Optimal left ventricular lead placement for cardiac resynchronization therapy in postmyocardial infarction patients.

Future Cardiol 2018 05 16;14(3):215-224. Epub 2018 May 16.

Cardiologia, Ospedale Santa Maria della Pietà, Nola, Napoli, Italy.

Aim: To evaluate at a 12-month follow-up, the clinical and echocardiographic outcomes in postmyocardial infarction (MI) heart failure patients who underwent cardiac resynchronization therapy (CRT) device implantation.

Materials & Methods: A total of 100 patients received a CRT device, and the study population was divided into three groups, according to the site of MI and left ventricular (LV) lead placed downstream of the ischemic area, as evaluated by echocardiography.

Results: At the end of the 12-month follow-up, we reported a general improvement of LV ejection fraction from 28 ± 7% to 35 ± 9% (p < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2017-0046DOI Listing
May 2018
1 Read

Highlights from the British Society for Heart Failure 20th Annual Autumn Meeting: three decades of heart failure.

Future Cardiol 2018 05 16;14(3):203-206. Epub 2018 May 16.

Hull York Medical School, Hull, HU6 7RX, UK.

The 20th Annual Autumn Meeting of the British Society for Heart Failure took place on the 23-24 November 2017 at the Queen Elizabeth II Conference Centre, London, UK. Over 800 delegates were in attendance: a multidisciplinary league of professionals who treat patients with heart failure, including specialist nurses, trainees, cardiologists, geriatricians, pharmacists and general practitioners. The theme of the conference was 'three decades of heart failure' and celebrated the success of modern heart failure management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2018-0013DOI Listing
May 2018
2 Reads

Eluvia drug-eluting vascular stent system for the treatment of symptomatic femoropopliteal lesions.

Future Cardiol 2018 05 10;14(3):207-213. Epub 2018 Apr 10.

Lankenau Heart Institute, Wynnewood, PA 19096, USA.

Endovascular options are increasingly recognized as primary treatments for lower extremity peripheral arterial disease inadequately responsive to noninvasive therapy. Options include balloon angioplasty and stent implantation, and newer technologies incorporate drug coatings to prevent restenosis and reduce the need for reintervention. The Eluvia drug-eluting vascular stent system (Boston Scientific, MA, USA) was designed with a biocompatible fluoropolymer coating to allow for drug elution over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fca-2017-0105DOI Listing
May 2018
7 Reads